ipilimumab,nivolumab,durvalumab,paclitaxel,vinorelbine,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
astrazeneca,bms
['optima', 'aegean', 'cm816']
#aacr23 #aegean 3yr 63% efs data (cpr 17%) presented comparable to #cm816 we shouldn t do cross-trial comparisons but we can t help ourselves and wonder: is all the benefit of io seen upfront in the neoadj setting? what is the optimal duration of io therapy for maximal 
Associate Director Community Outreach- DEI- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed